In vivo, FIASMAs lead to a relevant reduction of ceramide related to the inhibition of ASM and have been successfully used to reproduce the phenotype observed in ASM heterozygous mice in models of cystic fibrosis and major depression (4, 5). The gene discussed is SMPD1; the disease is cystic fibrosis.